Axel C Carlsson1, Juan-Jesús Carrero2, Peter Stenvinkel2, Matteo Bottai3, Peter Barany2, Anders Larsson4, Johan Ärnlöv5. 1. Centre for Family Medicine, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden ; Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden. 2. Department of Clinical Science, Intervention and Technology, Stockholm, Sweden. 3. Division of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. 4. Department of Medical Sciences, Uppsala University, Uppsala, Sweden. 5. Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden ; School of Health and Social Studies, Dalarna University, Falun, Sweden.
Abstract
OBJECTIVE: Circulating soluble tumor necrosis factor receptors 1 and 2 (sTNFR1 and sTNFR2) are associated with chronic kidney disease (CKD) progression in patients with CKD or diabetes, and with higher mortality. However, data in patients with end-stage renal disease are scarce. Therefore, we analyzed serum levels of sTNFR1 and sTNFR2 and investigated their association with inflammatory markers and mortality in dialysis patients. RESEARCH DESIGN AND METHODS: This was a longitudinal cohort study of 207 prevalent patients (median age 66 years, 56% men) undergoing hemodialysis in Stockholm, Sweden. Demographics, clinical characteristics, including comorbidities and laboratory data, were obtained at baseline, together with prospective follow-up for mortality. RESULTS: The median sTNFR1 and sTNFR2 levels were 17,680 ng/l [95% confidence interval (CI) 17,023-18,337] and 24,450 ng/l (95% CI 23,721-25,179), respectively. During a follow-up of 31 months (interquartile range, 21-38), 77 patients died. There was no association between the levels of sTNFRs and mortality in Cox regression models, and no consistent trend towards higher or lower mortality was seen in Laplace regression models. sTNFR1 and sTNFR2 levels were highly associated with other inflammatory markers including interleukin-6, pentraxin 3 and TNF-α. CONCLUSIONS: Prevalent hemodialysis patients have several-fold higher levels of sTNFRs compared to previous studies in CKD stage 4 patients. As no consistent association between TNFR and mortality was observed, clinical implications of measuring these receptors to predict outcome end-stage renal disease patients provide limited results.
OBJECTIVE: Circulating soluble tumor necrosis factor receptors 1 and 2 (sTNFR1 and sTNFR2) are associated with chronic kidney disease (CKD) progression in patients with CKD or diabetes, and with higher mortality. However, data in patients with end-stage renal disease are scarce. Therefore, we analyzed serum levels of sTNFR1 and sTNFR2 and investigated their association with inflammatory markers and mortality in dialysis patients. RESEARCH DESIGN AND METHODS: This was a longitudinal cohort study of 207 prevalent patients (median age 66 years, 56% men) undergoing hemodialysis in Stockholm, Sweden. Demographics, clinical characteristics, including comorbidities and laboratory data, were obtained at baseline, together with prospective follow-up for mortality. RESULTS: The median sTNFR1 and sTNFR2 levels were 17,680 ng/l [95% confidence interval (CI) 17,023-18,337] and 24,450 ng/l (95% CI 23,721-25,179), respectively. During a follow-up of 31 months (interquartile range, 21-38), 77 patients died. There was no association between the levels of sTNFRs and mortality in Cox regression models, and no consistent trend towards higher or lower mortality was seen in Laplace regression models. sTNFR1 and sTNFR2 levels were highly associated with other inflammatory markers including interleukin-6, pentraxin 3 and TNF-α. CONCLUSIONS: Prevalent hemodialysis patients have several-fold higher levels of sTNFRs compared to previous studies in CKD stage 4 patients. As no consistent association between TNFR and mortality was observed, clinical implications of measuring these receptors to predict outcome end-stage renal diseasepatients provide limited results.
Authors: Dominik N Muller; Erdenechimeg Shagdarsuren; Joon-Keun Park; Ralf Dechend; Eero Mervaala; Franziska Hampich; Anette Fiebeler; Xinsheng Ju; Piet Finckenberg; Jürgen Theuer; Christiane Viedt; Joerg Kreuzer; Harald Heidecke; Hermann Haller; Martin Zenke; Friedrich C Luft Journal: Am J Pathol Date: 2002-11 Impact factor: 4.307
Authors: Jorge M Luna; Yeseon Moon; Khin Liu; Steven Spitalnik; Myunghee Paik; Ralph Sacco; Mitchell S V Elkind Journal: Age Ageing Date: 2013-01-15 Impact factor: 10.668
Authors: Sunna Snaedal; Olof Heimbürger; Abdul Rashid Qureshi; Anders Danielsson; Björn Wikström; Bengt Fellström; Ingela Fehrman-Ekholm; Juan Jesús Carrero; Anders Alvestrand; Peter Stenvinkel; Peter Bárány Journal: Am J Kidney Dis Date: 2009-04-25 Impact factor: 8.860
Authors: Andrzej S Krolewski; Monika A Niewczas; Jan Skupien; Tomhito Gohda; Adam Smiles; Jon H Eckfeldt; Alessandro Doria; James H Warram Journal: Diabetes Care Date: 2013-08-12 Impact factor: 19.112
Authors: Jia Sun; Jonas Axelsson; Anna Machowska; Olof Heimbürger; Peter Bárány; Bengt Lindholm; Karin Lindström; Peter Stenvinkel; Abdul Rashid Qureshi Journal: Clin J Am Soc Nephrol Date: 2016-06-08 Impact factor: 8.237
Authors: Axel C Carlsson; Toralph Ruge; Erik Kjøller; Jørgen Hilden; Hans Jørn Kolmos; Ahmad Sajadieh; Jens Kastrup; Gorm Boje Jensen; Anders Larsson; Christoph Nowak; Janus Christian Jakobsen; Per Winkel; Christian Gluud; Johan Ärnlöv Journal: J Am Heart Assoc Date: 2018-04-23 Impact factor: 5.501
Authors: Susana Coimbra; Susana Rocha; Henrique Nascimento; Maria João Valente; Cristina Catarino; Petronila Rocha-Pereira; Maria Sameiro-Faria; José Gerardo Oliveira; José Madureira; João Carlos Fernandes; Vasco Miranda; Luís Belo; Elsa Bronze-da-Rocha; Alice Santos-Silva Journal: Clin Kidney J Date: 2020-08-24